ACEPODIA
Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell compatible chemistry to attach tumor-targeting antibodies directly to a variety of immune cell receptors, enhancing the lock between immune and cancer cells and generating highly specific, potent cell therapies without the need for genetic engineering. Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.
ACEPODIA
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Alameda, California, United States
Country:
United States
Website Url:
http://www.acepodia.com
Total Employee:
51+
Status:
Active
Contact:
(415) 366 7822
Total Funding:
256 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager Google Analytics Content Delivery Network LetsEncrypt SSL By Default Global Site Tag
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Investors List
Digital Mobile Venture
Digital Mobile Venture investment in Series D - Acepodia
Digital Mobile Venture
Digital Mobile Venture investment in Series C - Acepodia
DEFTA Partners
DEFTA Partners investment in Series B - Acepodia
8VC
8VC investment in Series B - Acepodia
CDIB Capital
CDIB Capital investment in Series B - Acepodia
Ridgeback Capital
Ridgeback Capital investment in Series B - Acepodia
Key Employee Changes
| Date | New article |
|---|---|
| 2023-09-18 | Acepodia Announces Nobel Laureate Carolyn Bertozzi, Ph.D., as Chief Scientific Advisor |
Official Site Inspections
http://www.acepodia.com Semrush global rank: 6.94 M Semrush visits lastest month: 976
- Host name: li1761-146.members.linode.com
- IP address: 172.104.170.146
- Location: Singapore Singapore
- Latitude: 1.2929
- Longitude: 103.8547
- Timezone: Asia/Singapore
- Postal: 18
More informations about "Acepodia"
Acepodia - Crunchbase Company Profile & Funding
Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell …See details»
Company Organization-Acepodia | POWERFUL, ACCESSIBLE CELL …
We sincerely thank you for your support to Acepodia. Personal Investment and Stock Affairs Agent Information PHONE: +886-2-xxxxxxxx. ADDRESS: xxxxxxxxxxx. Professional …See details»
Leadership-Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES …
Dr. Yang is the Chairman and Co-Founder of Acepodia. Dr. Yang was formerly Executive Vice President at Juno Therapeutics. Prior to Juno, he served as Executive Vice President of …See details»
Acepodia - LinkedIn
Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients.See details»
Acepodia Biotech, Inc. - Drug pipelines, Patents, Clinical trials
ACE1831 is a potential antibody‑armed allogeneic gamma delta T cell therapy developed using Acepodia's unique antibody-cell conjugation (ACC) technology as an optimized T cell engager …See details»
Acepodia - Overview, News & Similar companies | ZoomInfo.com
View Acepodia (www.acepodia.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more. …See details»
Acepodia Company Profile 2024: Stock Performance & Earnings
Acepodia General Information Description. Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using …See details»
Acepodia Company Profile - Office Locations, Competitors ... - Craft
Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's …See details»
Acepodia - Funding, Financials, Valuation & Investors - Crunchbase
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. ... How much …See details»
Acepodia is pioneering next-generation cell therapy.
Acepodia was spun-off from Professor Carolyn Bertozzi 's lab who won the 2022 Nobel Prize for Chemistry and founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche and Genentech, and by Dr. Sonny Hsiao, …See details»
Acepodia: Contact Details, Revenue, Funding, Employees and …
Acepodia is a clinical-stage biotechnology company developing accessible cancer cell therapies using its Antibody-Cell Conjugation (ACC) technology. By linking tumor-targeting antibodies to …See details»
Member Profile - TRPMA Official Website
Jun 19, 2017 Acepodia was founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche, and Genentech, and by Dr. Sonny Hsiao, UC Berkeley Cell Biologist …See details»
Acepodia Information - RocketReach
Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell …See details»
Acepodia Secures $100 Million Series D Financing to Advance First …
Jun 6, 2023 Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address …See details»
Acepodia snags $109M—and an early Zoom backer—to ... - Fierce …
Dec 2, 2021 Elsewhere in the C-suite, Acepodia has gone on a hiring spree since disclosing a $47 million series B in March. AbbVie cancer R&D veteran Thorsten Graef, M.D., Ph.D., joined …See details»
Acepodia raises funds to advance pipeline of cell therapies
Acepodia will use the proceeds from the Series D round to advance its cell therapies pipeline, including ACE1831 and ACE2016, to treat solid tumours and haematologic cancers. ACE1831 …See details»
Acepodia Enters Strategic Clinical Collaboration with Pfizer to ...
Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. …See details»
Company Overview-Acepodia | POWERFUL, ACCESSIBLE CELL …
If you have any questions or suggestions about investor services, please email [email protected]. We sincerely thank you for your support to Acepodia. Personal Investment and Stock Affairs …See details»
Acepodia Announces 2025 Clinical Development Milestones and ...
Dec 13, 2024 Acepodia (The Company, 6976.TT) announced today at the investor conference the clinical trial progress for its core product candidates ACE1831 and ACE2016, along with a …See details»